TrialClinical pharmacokinetics2018

Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials.

Amit Khatri et al.PubMed ↗Publisher ↗

No numbers read from the abstract.